Analogous to the history of systemic therapies in advanced ccRCC, the prospective trials in papillary RCC initially focused on VEGFR TKI monotherapies, with cabozantinib (inhibitor of MET, AXL, and VEGFR2) outperforming sunitinib (inhibitor of PDGFR, VEGFR1-3, KIT, and RET) in the only direct comparison of these agents [5]. This evidence concerns the gene KIT and nonpapillary renal cell carcinoma.